Abstract
A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.
Alfons den Broeder, Leo van de Putte, Rolf Rau, Manfred Schattenkirchner, Piet Van Riel, Oliver Sander, Christina Binder, Helmut Fenner, Yvonne Bankmann, Raja Velagapudi, Joachim Kempeni and Hartmut Kupper
The Journal of Rheumatology November 2002, 29 (11) 2288-2298;
Alfons den Broeder
Leo van de Putte
Rolf Rau
Manfred Schattenkirchner
Piet Van Riel
Oliver Sander
Christina Binder
Helmut Fenner
Yvonne Bankmann
Raja Velagapudi
Joachim Kempeni
In this issue
A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.
Alfons den Broeder, Leo van de Putte, Rolf Rau, Manfred Schattenkirchner, Piet Van Riel, Oliver Sander, Christina Binder, Helmut Fenner, Yvonne Bankmann, Raja Velagapudi, Joachim Kempeni, Hartmut Kupper
The Journal of Rheumatology Nov 2002, 29 (11) 2288-2298;
A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.
Alfons den Broeder, Leo van de Putte, Rolf Rau, Manfred Schattenkirchner, Piet Van Riel, Oliver Sander, Christina Binder, Helmut Fenner, Yvonne Bankmann, Raja Velagapudi, Joachim Kempeni, Hartmut Kupper
The Journal of Rheumatology Nov 2002, 29 (11) 2288-2298;